NCT01068782 2026-02-25Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second RelapseExelixisPhase 2 Terminated19 enrolled 10 charts
NCT01995058 2026-01-08Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCExelixisPhase 2 Terminated54 enrolled 11 charts
NCT03634540 2024-12-20MK-6482-003Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 2 Active not recruiting118 enrolled
NCT00940225 2024-04-25Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesExelixisPhase 2 Completed730 enrolled 25 charts